Have a feature idea you'd love to see implemented?
Let us know!
ETON Eton Pharmaceuticals Inc
Price (delayed)
$8.19
Market cap
$211.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$198.71M
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI®
Highlights
The debt has declined by 22% year-on-year and by 4.3% since the previous quarter
The revenue is up by 9% YoY but it is down by 8% QoQ
The quick ratio has plunged by 52% YoY and by 9% from the previous quarter
ETON's equity is down by 20% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of ETON
Market
Valuations
Earnings
Shares outstanding
25.84M
Market cap
$211.6M
Enterprise value
$198.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
15.63
Price to sales (P/S)
6.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.14
Revenue
$32.38M
EBIT
-$7.08M
EBITDA
-$6.05M
Free cash flow
$28,000
Per share
Balance sheet
Liquidity
EPS
-$0.26
Free cash flow per share
$0
Book value per share
$0.52
Revenue per share
$1.26
TBVPS
$1
Total assets
$31.82M
Total liabilities
$18.36M
Debt
$4.8M
Equity
$13.46M
Working capital
$7.22M
Debt to equity
0.36
Current ratio
1.4
Quick ratio
1.24
Net debt/EBITDA
2.13
Margins
Efficiency
Dividend
EBITDA margin
-18.7%
Gross margin
60.7%
Net margin
-20.7%
Operating margin
-16.3%
Return on assets
-21.2%
Return on equity
-43.6%
Return on invested capital
N/A
Return on capital employed
-52%
Return on sales
-21.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ETON stock price
How has the Eton Pharmaceuticals stock price performed over time
Intraday
0.74%
1 week
-2.5%
1 month
42.43%
1 year
114.4%
YTD
86.99%
QTD
36.5%
Financial performance
How have Eton Pharmaceuticals's revenue and profit performed over time
Revenue
$32.38M
Gross profit
$19.67M
Operating income
-$5.28M
Net income
-$6.69M
Gross margin
60.7%
Net margin
-20.7%
The gross margin has contracted by 18% YoY and by 10% from the previous quarter
Eton Pharmaceuticals's gross profit has decreased by 17% from the previous quarter and by 11% YoY
The revenue is up by 9% YoY but it is down by 8% QoQ
Growth
What is Eton Pharmaceuticals's growth rate over time
Valuation
What is Eton Pharmaceuticals stock price valuation
P/E
N/A
P/B
15.63
P/S
6.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.14
The stock's price to book (P/B) is 140% more than its last 4 quarters average of 6.5 and 14% more than its 5-year quarterly average of 13.7
ETON's equity is down by 20% year-on-year and by 13% since the previous quarter
ETON's P/S is 117% above its last 4 quarters average of 3.0 but 98% below its 5-year quarterly average of 279.8
The revenue is up by 9% YoY but it is down by 8% QoQ
Efficiency
How efficient is Eton Pharmaceuticals business performance
Dividends
What is ETON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ETON.
Financial health
How did Eton Pharmaceuticals financials performed over time
ETON's total assets is 73% more than its total liabilities
The quick ratio has plunged by 52% YoY and by 9% from the previous quarter
Eton Pharmaceuticals's current ratio has decreased by 49% YoY and by 12% from the previous quarter
The debt is 64% smaller than the equity
The debt has declined by 22% year-on-year and by 4.3% since the previous quarter
ETON's equity is down by 20% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.